-
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted...
IN THE SPOTLIGHT
-
Initial Treatment Options for HER2+ NSCLC Expand with New Zongertinib Approval
On February 26, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) as an initial treatment option for newly diagnosed... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Accelerated Approval for HER2-positive NSCLC
On November 19, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sevabertinib (Hyrnuo®) to treat patients with locally-advanced or metastatic... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000...
Spectroscopic and quantum chemical characterization of 4-[2-(2-Amino-4,7-dihydro-4-oxo-3 H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid with molecular docking and cytotoxicity insights for targeting NSCLC
Spectroscopic and quantum chemical characterization of 4-[2-(2-Amino-4,7-dihydro-4-oxo-3 H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid with molecular docking and cytotoxicity insights for targeting NSCLC
Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC
A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S–mutant NSCLC
A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S–mutant NSCLC
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC
FDA Approval Insights: Zongertinib for HER2 TKD–Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
FDA Approval Insights: Zongertinib for HER2 TKD–Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD
Zongertinib a ‘breakthrough’ first-line treatment for NSCLC with HER2 mutations
Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models
Precision in Pharmacoeconomics: A Comparative Cost-Utility Analysis of Osimertinib in EGFR-Mutant NSCLC Using Traditional and Pharmacometric Models
Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC
Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026